SeaStar Medical Posts $4.5M Q3 Net Loss as Operating Expenses Hit $5.2M
ICU is trading near its 52-week low of $1.84 (4.3% above the low).
Summary
SeaStar Medical reported a Q3 net loss of $4.529 million and an operating loss of $4.581 million on $5.168 million of operating expenses, with EPS of -$1.03, on Q3 revenue of $635,000. The loss dwarfs that quarterly revenue, so the business is still burning far more than it brings in. That matters because the last 10-Q showed cash down to $7.0 million with management flagging substantial going-concern doubt — a quarterly burn of this size puts the runway under real pressure. The company has been leaning on capital markets to stay funded, including the October warrant inducement that raised $3.3 million and the S-3 filed October 30 to register the underlying shares. The regulatory side has been the bright spot: FDA Breakthrough Device Designation for the SCD in October and CBER's November 3 determination that the pediatric SAVE registry satisfied post-approval obligations. Watch for the 10-Q filing and any new 424B prospectus supplement under the shelf, which would show fresh dilution.
At the time of this announcement, ICU was trading at $1.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2M. The 52-week trading range was $1.84 to $5.38. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.